<table>
<thead>
<tr>
<th>Vaccine key</th>
<th>BCG: tuberculosis; Hib: <em>Haemophilus influenzae</em> type b; HPV: human papillomavirus; MMR: measles, mumps, rubella; Tdap: tetanus, diphtheria, acellular pertussis; varicella: chickenpox.</th>
</tr>
</thead>
</table>

### Influenza Immunisation Programme
- Pregnancy,
- Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness,
- Individuals aged 6 months to under 65 years with an eligible medical condition,
- Individuals aged 65 years or older.

### Influenza vaccine
- Kidney disease
- Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines

### Liver disease
- Hepatitis A and varicella vaccines

### Meningococcal disease case — contact with
- Meningococcal vaccine

### Needle stick injury — following
- Hepatitis B vaccine

### Non-consensual sexual intercourse — following
- Hepatitis B vaccine

### Pneumococcal disease — increased risk
- Additional pneumococcal vaccines

### Pregnancy
- Influenza and Tdap vaccines in every pregnancy

### Rubella — women of childbearing age who are not immune to rubella
- MMR vaccine

### Solid organ transplantation
- Prior to solid organ transplantation
  - Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines
- Following solid organ transplantation
  - Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines

### Tuberculosis — infants and children aged under 5 years at risk of tuberculosis (TB) exposure
- BCG vaccine

---

### Asplenia — Functional or Pre- or Post-Splenectomy Immunisation Programme
- Hib, influenza, meningococcal, pneumococcal, and Tdap vaccines

### Chemotherapy — following
- Hib, HPV, influenza, pneumococcal, Tdap, and varicella vaccines

### Cochlear implant
- Hib, influenza, and pneumococcal vaccines

### Error of metabolism at risk of major metabolic decompensation
- Influenza and varicella vaccines

### Haematopoietic stem cell transplantation (HSCT) — following
- Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, and varicella vaccines

### Hepatitis A case — contact with
- Hepatitis A vaccine

### Hepatitis B case — contact with
- Hepatitis B vaccine

### Hepatitis A positive individual
- Hepatitis B vaccine

### Hepatitis C positive individual
- Hepatitis B vaccine

### HIV positive individual
- Hepatitis B, HPV, influenza, meningococcal, pneumococcal, and varicella vaccines

### Immune deficiency/immunosuppression
- Individuals with an immune deficiency
  - Influenza, meningococcal, and pneumococcal vaccines
- Household contacts of children or adults who will be/are immunosuppressed
  - Varicella vaccine
- Prior to elective immunosuppression for longer than 28 days
  - Varicella vaccine
- Following immunosuppression for longer than 28 days
  - Hib, influenza, meningococcal, and Tdap vaccines

---

Please refer to individual vaccines for detailed eligibility criteria and to the electronic *Immunisation Handbook 2014 (3rd edition)* for vaccine administration schedules.
## Funded vaccines for special groups from 1st January 2017

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Individuals eligible for funded vaccine</th>
</tr>
</thead>
</table>
| **Hepatitis A vaccine**                    | • One dose for close contacts of a hepatitis A case  
• Two doses for transplant patients; or children with chronic liver disease                                                                                                                                                    |
| **Hepatitis B vaccine**                    | • Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*; non-consensual sexual intercourse; or needle stick injury (5mcg/0.5mL or 10mcg/1.0mL as appropriate)  
• Children under the age of 18 years who are considered not to have achieved a positive serology and require additional vaccination (5mcg/0.5mL or 10mcg/1.0mL as appropriate)  
• Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg/1.0mL)                                                                                                               |
| **Haemophilus influenzae type b (Hib) vaccine** | • An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen                                                                                             |
| **Human papillomavirus (HPV) vaccine**      | • Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive  
• A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy                                                                                                                                         |
| **Influenza vaccine**                       | • Pregnant women in every pregnancy during vaccination season  
• Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness  
• Individuals aged 65 years and older  
• Individuals aged 6 months to under 65 years with certain medical conditions, as per the Influenza Kit, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation |
| **Meningococcal conjugate vaccines**        | • One dose for a close contacts of meningococcal disease case  
• Two doses for individuals post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*  
• Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive |
| **Tetanus, diphtheria and pertussis (Tdap) vaccine** | • One dose for pregnant women, between gestational weeks 28 and 38 of every pregnancy  
• Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen |


* For example chemotherapy regimens to treat cancer, conditioning regimes prior to haematopoietic stem cell transplantation, and treatment of immune mediated inflammatory disease.
### Funded vaccines for special groups from 1st January 2017

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Individuals eligible for funded vaccine</th>
</tr>
</thead>
</table>
| **Pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (23PPV) vaccines** (Chapter 15) | **PCV13:**  
  - One dose for high-risk children aged 18 months to under 18 years who have previously received four doses of PCV10  
  - Up to an additional four doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive  

  **23PPV:**  
  - Up to two doses (as appropriate) for high-risk children aged 2 years to under 18 years, or  
  - Up to three doses (as appropriate) for individuals aged 18 years or older who are:  
    - Post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive |
| **BCG vaccine (Bacillus Calmette-Guérin)** (Chapter 20) | **All public health community BCG Vaccination Clinics and in-hospital vaccinations are postponed until further notice, due to a global shortage of BCG vaccine.**  
  **Eligibility when BCG Vaccination Clinics are operational:**  
  - Infants at increased risk of tuberculosis (TB) exposure  
  - Children aged under 5 years at risk of TB exposure |
| **Varicella vaccine** (Chapter 21) | **Two doses for non-immune individuals:**  
  - Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist  
  - Prior to elective immunosuppressive therapy that will be longer than 28 days  
  - With chronic liver disease who may in future be candidates for transplantation  
  - With deteriorating renal function before transplantation  
  - Pre-solid organ transplantation  
  - Post-haematopoietic stem cell transplantation, on the advice of their specialist  
  - Post-chemotherapy, on the advice of their specialist  

  **Two doses for individuals with no clinical history of varicella infection or immunisation:**  
  - With an inborn error of metabolism at risk of major metabolic decompensation  
  - Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection of immunisation  
  - Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation |

---


Ψ For example treatment of immune mediated inflammatory disease.

---

GET THE FACTS ON IMMUNISATION

Fact sheet January 2017